Back to Directory
Terlipressin
Performance & EnduranceLong-acting vasopressin analog for variceal bleeding and hepatorenal syndrome.
Key Benefits
- ✓Treats variceal bleeding
- ✓Manages hepatorenal syndrome
- ✓Splanchnic vasoconstriction
- ✓Longer duration than vasopressin
- ✓Reduces portal pressure
Dosing Information
Dosage Range
1-2 mg
Frequency
Every 4-6 hours or continuous
Typical Duration
Until condition resolves
Detailed Protocol
Administered via intravenous infusion or bolus in hospital setting. For HRS, continuous or intermittent dosing. ICU or hospital setting only.
About Terlipressin
Terlipressin is a synthetic vasopressin analog that is a prodrug converted to lysine vasopressin. It has prolonged action and is used for bleeding esophageal varices and hepatorenal syndrome. Approved in many countries, FDA-approved in 2022 for hepatorenal syndrome.
Research Notes
FDA-approved in 2022 for hepatorenal syndrome (Terlivaz). Widely used internationally for variceal bleeding. More convenient than vasopressin due to longer half-life.
Potential Side Effects
- •Ischemia risk
- •Hyponatremia
- •Abdominal pain
- •Diarrhea
- •Respiratory disorders
- •Requires ICU monitoring
Always consult with a healthcare professional before starting any peptide therapy.